The primary objective of the open-label extension was to evaluate the long-term safety and tolerability of a transdermal rivastigmine patch up to 1 year, as a novel approach to treatment in Alzheimer disease. This was a 28-week extension to a 24-week, double-blind, double-dummy, placebo-controlled, and active-controlled study evaluating rivastigmine patches [9.5 mg/24 h (10 cm 2 ) and 17.4 mg/24 h (20 cm 2 )] and oral capsules (3 to 6 mg twice-daily). Patients entering the extension were switched directly to 9.5 mg/ 24 h rivastigmine patch and increased to 17.4 mg/24 h patch, irrespective of their double-blind study treatment. Primary measures included safety and tolerability assessments, including adverse events and serious adverse events. Of 1195 patients randomized to treatment, 870 (72.8%) completed the double-blind study and entered the open-label extension. During weeks 1 to 4 of the extension, 9.5 mg/24 h rivastigmine patch was well tolerated overall by patients formerly randomized to rivastigmine capsule or patch groups: r2.5% reported nausea and r1.9% reported vomiting. No unexpected safety issues arose, and skin tolerability was good; similar to the double-blind study. During the 28-week, open-label extension phase, the patch seemed to be well tolerated with a favorable safety profile.
A lzheimer disease (AD) is characterized by cholinergic deficits primarily in the cortex and hippocampus. 1 Cholinesterase inhibitors, which currently form the mainstay of AD therapy in many countries worldwide, act by inhibiting the degradation of acetylcholine in the synapse.
Rivastigmine is an inhibitor of acetylcholinesterase and butyrylcholinesterase, and is widely approved for the symptomatic treatment of mild to moderate AD and Parkinson disease dementia. Until recently, all cholinesterase inhibitors were administered orally, but a novel rivastigmine transdermal patch has now been developed. Patches provide smooth and continuous drug delivery through the skin and into the bloodstream, avoiding firstpass effects in the gut and the liver 2 and offering potential benefits over conventional oral administration in patients with AD.
Acute or protracted gastrointestinal adverse events (AEs), such as nausea and vomiting, are typically observed with orally administered cholinesterase inhibitors, and may result in discontinuation of therapy. 3 These events have been associated with high plasma concentrations (C max ) and short time to C max (t max ). 4 Measures that reduce C max and prolong t max (such as smoother drug delivery) can help to reduce the incidence of these AEs, 5 allowing easier access to optimal therapeutic doses and better compliance to treatment.
Pharmacokinetic studies in AD patients have shown that the 9.5 mg/24 h rivastigmine patch (10 cm 2 ) delivers comparable levels of drug exposure to the highest dose of capsules (12 mg/d), with a smoother pharmacokinetic profile (lower C max and longer t max ). 5 Consistent with these observations, comparable efficacy on measures of both cognition and activities of daily living, but with only onethird the incidence of nausea or vomiting, were reported for the 9.5 mg/24 h rivastigmine patch versus highest doses of conventional capsules (12 mg/d) in the 24-week, doubleblind, randomized study. 6 Furthermore, results from the double-blind study showed that caregivers of AD patients preferred the rivastigmine patch to capsules. 7 Patches allow the caregiver to manage treatment effectively, act as a visual reminder, and may help improve compliance. This, in turn, may further enhance the efficacy of the treatment. 8 To date, only short-term studies of the efficacy, safety, and tolerability of the rivastigmine patch have been reported. The primary objective of this open-label extension to a 24-week, double-blind, randomized study was to evaluate the safety and tolerability of rivastigmine patch treatment up to 1 year. The study was also designed to provide data that could help develop guidance for physicians when switching patients from rivastigmine capsules to the 9.5 mg/24 h rivastigmine patch. each patient and caregiver before randomization. Consent was not requested for the open-label extension phase.
Patients eligible for the double-blind study were men or women aged 50 to 85 years with a mini-mental state examination 9 score of 10 to 20 and diagnoses of dementia of the Alzheimer type 10 and probable AD. 11 Patients with an advanced, severe, progressive, or unstable disease, which could explain the dementia, were excluded from the study. The use of investigational drugs, cholinesterase inhibitors, memantine, or any other approved treatment for AD during the 4 weeks before randomization was also prohibited.
All patients completing the double-blind study were eligible to enter the open-label extension phase, irrespective of their former double-blind study treatment group [9.5 mg/ 24 h rivastigmine patch, 17.4 mg/24 h rivastigmine patch (20 cm 2 ), 12 mg/d rivastigmine capsule, or placebo]. Upon entry into the open-label extension, all patients were to begin treatment directly with a 9.5 mg/24 h rivastigmine patch dose. Patients' doses were then raised in 4-week steps to a 13.3 mg/24 h (15 cm 2 ) and then a 17.4 mg/24 h rivastigmine patch, dependent upon tolerability, and maintained at this or their highest tolerated dose for the remainder of the extension. Adjustments to the treatment dose (interruptions or dose decreases) were permitted to address any safety or tolerability issues.
Patches were administered by the caregiver to clean, dry, hairless skin on the patient's upper back every morning and worn for 24 hours. Normal activities, including bathing, were permitted. To minimize any skin irritation the application-site of the patch was alternated daily between the left and the right sides.
In this article, ''baseline'' refers to week 0 (the beginning of the double-blind study), ''week 24'' corresponds to the end of the double-blind study and the beginning of the open-label extension, and ''week 52'' to the end of the open-label extension.
Outcome Measures
The primary objective of the open-label extension phase was to evaluate the long-term safety and tolerability of the rivastigmine patch. Assessments were made at weeks 24, 28, 32, 36, 40, 46, and 52. Safety evaluations consisted of recording all AEs and serious adverse events (SAEs), together with ratings of their severity and relationship to the study drug, and recording patients' vital signs. At each study visit, skin irritation was assessed by an investigator using a specific rating scale to record the severity of individual symptoms. Summary evaluations of skin irritation since the last visit were provided by the caregiver via a specific questionnaire. Routine laboratory tests were performed at week 24, but not thereafter, unless required for investigative or diagnostic purposes. Any abnormal clinical laboratory findings associated with symptoms considered clinically significant or that required therapy were recorded as AEs.
Efficacy outcomes were recorded at week 24 and at week 52 as secondary measures for the open-label extension. These included the Alzheimer Disease Assessment Scale-Cognitive subscale (ADAS-cog), 12 Alzheimer Disease Cooperative Study-Clinical Global Impression of Change, 13 and Alzheimer Disease Cooperative Study-Activities of Daily Living scale. 14 An additional ADAS-cog evaluation was performed at week 40. To ensure standar-dization of the efficacy measures investigators received specific training before patient evaluation.
Statistical Analyses
There was no prospective sample size calculation for the open-label extension, as all patients who completed the double-blind study 6 and were willing and able to participate in the extension phase were included.
For the open-label extension phase, safety and tolerability data were tabulated. These data are presented by former randomized treatment group and overall population. Tolerability data are presented by the full 28week duration and by weeks 25 to 28 to establish the effects of switching from each double-blind study treatment to the 9.5 mg/24 h patch. Efficacy data are also presented in a descriptive way.
The open-label ''safety population'' was defined as all patients who had at least 1 dose of study medication and at 
RESULTS

Patients
Of the 1195 patients who were initially randomized to the primary trial, 1190 received treatment and 970 completed the double-blind study. Of these, 870 patients entered the open-label extension and received at least 1 dose of study medication; 209 (24.0%) were formerly randomized to the 17.4 mg/24 h patch, 204 (23.5%) to the 9.5 mg/24 h patch, 209 (24.0%) to capsules, and 248 (28.5%) to placebo. The intent-to-treat observed case population comprised 780 patients (72.9% formerly randomized to active rivastigmine treatment and 27.1% to placebo). In total, 704 patients (80.9%) completed the open-label extension ( Fig. 1 ) and 166 patients discontinued.
For the 870 patients entering the open-label extension phase, the mean age at baseline was 73.5 years, 66% were women, and the mean duration of AD (since first diagnosis by a physician) was 1.1 years. Baseline demographics and background characteristics are summarized in Table 1 ; these were similar to the baseline characteristics of the 1195 patients who entered the double-blind study, 6 suggesting an absence of dropout bias. The majority of the study population received concomitant medication during the open-label extension, of which 43.3% received central nervous system-related medications, most commonly sedatives, antidepressants, and antipsychotics; 75.6% received non-central nervous system-related medications, most commonly acetylsalicylic acid (24.6%) and angiotensinconverting enzyme inhibitors for hypertension (21.3%). Concomitant memantine, cholinesterase inhibitors, or other approved treatments for AD were not permitted during the study.
Safety and Tolerability
During the first 4 weeks of the open-label extension (weeks 25 to 28), patients formerly randomized to rivastigmine treatment (capsule or patch) reported fewer AEs than those formerly randomized to placebo (r15.2% vs. 28.2%). This prior exposure effect was noted for nausea (r2.5% vs. 8.5%) and vomiting (r1.9% vs. 6.0%) ( Table 2) .
A total of 501 patients (57.6%) reported AEs during the full open-label extension (weeks 25 to 52). These were predominantly cholinergic in nature and mild to moderate in severity, with nausea and vomiting reported most frequently (15.7% and 14.3%, respectively) ( Table 3) . As anticipated, patients formerly randomized to 17.4 mg/24 h patch or capsule treatment during the doubleblind study reported fewer gastrointestinal AEs than those formerly randomized to 9.5 mg/24 h or placebo.
Skin tolerability at the application site was good. During the open-label extension, over 90% of all patients experienced ''no, slight, or mild'' irritation as their most severe application-site skin reaction, comparable with the results from the double-blind study. 6 The symptoms that were most commonly reported as moderate or severe on the skin irritation rating scale were erythema and pruritus (7.7% and 5.6%, respectively). A minority of patients (3.7%) withdrew owing to application-site skin reactions. With the exception of the week 28 assessment, the proportion of patients who reported no skin irritation remained similar throughout the entire 52-week study period. In addition, there was no trend toward an increase in the severity of adverse skin reactions over time (5.0% and 2.6% reported moderate irritation at weeks 24 and 52, respectively; 1.6% and 1.5% reported severe irritation).
SAEs occurred in 1.0% (n = 9) of patients during the first 4 28) and 9.4% (n = 82) of patients during the full open-label extension phase (weeks 25 to 52). Most common were gastrointestinal disorders (2.0%), infections and infestations (2.0%), cardiac disorders (1.7%), and nervous system disorders (1.5%). The most frequent of these included vomiting (0.9%; n = 8), cerebrovascular accident (0.5%; n = 4), nausea (0.3%; n = 3), and cardiac failure (0.3%; n = 3). There was no clear pattern of SAE associated with the switch from placebo to rivastigmine patch treatment.
Seventy-three patients (8.4%) discontinued owing to AEs during the full 28-week extension phase, 15 (1.7%) of these owing to SAEs. The events that most frequently led to discontinuation of treatment were application-site reactions (3.6%; n = 31) and gastrointestinal disorders (2.9%; n = 25). Twenty-one patients (2.4%) discontinued during the first 4 weeks of the open-label extension: 11 patients (4.4%) were from the initial placebo group, 6 (2.9%) were from the rivastigmine capsule group, and 2 (1%) were from each of the 17.4 mg/24 h and 9.5 mg/24 h rivastigmine patch groups.
Eight deaths occurred during the open-label extension phase and a further 2 occurred during the 30-day follow-up period. The causes of death were as expected for an elderly population with AD, most commonly cardiac disorders (n = 5) and nervous system disorders (n = 3). None were considered treatment related.
Efficacy
At week 52, 632 patients (72.6%) had achieved the target patch size of 17.4 mg/24 h for at least 1 dose.
Upon entering the open-label extension phase and switching to the 9.5 mg/24 h rivastigmine patch, patients formerly randomized to placebo experienced a 1.3-point increase in their ADAS-cog scores during weeks 24 to 40. However, versus baseline, there was no overall significant change in ADAS-cog score at week 40 in this group {a 0.4-point increase vs. baseline; 95% confidence interval (CI) = À 1.4, 0.6 [not significant (ns)]; Fig. 2} . The increase in ADAS-cog score observed when placebo patients switched to the 9.5 mg/24 h rivastigmine patch was not sustained beyond week 40, and by week 52 declined to a level just below those patients who had also received rivastigmine in the double-blind phase (weeks 0 to 24; Fig. 2 ). 6 Patients receiving rivastigmine treatment for the entire study (weeks 0 to 52) showed a deterioration of 0.3 points [95% CI = À 0.4; 0.9 (ns)] on the ADAS-cog at week 52, whereas those receiving placebo for weeks 0 to 24, followed by the patch, showed a deterioration of 0.9 points [95% CI = À 0.4, 2.1 (ns); Table 4 ].
DISCUSSION
After 24-week treatment with the rivastigmine patch, no new safety or tolerability issues were reported during the 28-week extension phase in patients with mild to moderate AD. Skin tolerability was good. Acute gastrointestinal side effects, such as nausea and vomiting, were most commonly reported after dose increases, but more infrequently in patients who had previously received double-blind study rivastigmine treatment. Overall, these AEs were generally manageable and led to fewer than 3% of patients discontinuing treatment. Switching from any form of 
Double-blind study
Open-label extension phase Improvement rivastigmine treatment to the 9.5 mg/24 h rivastigmine patch was well tolerated. Patients switching from placebo directly to the 9.5 mg/24 h rivastigmine patch reported a higher incidence of gastrointestinal side effects during the first 4 weeks of the open-label extension. When switching directly to the 9.5 mg/24 h rivastigmine patch at the start of the open-label extension, patients formerly randomized to rivastigmine treatment (capsule or patch) had a lower incidence of nausea (r2.5% in any group) and vomiting (r1.9% in any group) during the first 4 weeks than those formerly randomized to placebo (8.5% and 6.0% for nausea and vomiting, respectively). These findings suggest that patients on high rivastigmine capsule doses may be switched directly to the 9.5 mg/24 h patch, whereas de novo patients and probably those on low doses should undergo 4 weeks of 4.6 mg/24 h (5 cm 2 ) patch treatment before raising their dose to 9.5 mg/24 h. 15 The rivastigmine patch demonstrated good skin tolerability throughout the open-label extension phase, with any reactions being usually mild in severity. Consequently, discontinuations owing to application-site skin reactions were low (3.7%), and were similar to the rates reported in the double-blind study.
Although the primary focus of the open-label extension was safety and tolerability, efficacy data were also recorded. The natural deterioration of ADAS-cog points varies greatly from study to study; some reporting 9 to 11 points per year, 16 others 6.4 points per year. 17 A recent meta-analysis of placebo-treated AD patients defined slow disease progression as a <4-point decline of ADAS-cog scores per year. 18 In this study, patients receiving rivastigmine therapy (patch or capsule) for the entire 52-week period exhibited a cognitive deterioration of only 0.3 points on ADAS-cog. This suggests that rivastigmine patch treatment provides sustained cognitive and functional benefits up to 1 year, which is consistent with findings from previous studies into oral rivastigmine treatment. 19 Patients who received placebo during the double-blind study exhibited a stabilization of ADAS-cog scores over the open-label extension, leading to an overall 52-week decline of 0.9 points. However, at week 52, patients formerly randomized to rivastigmine treatment tended to have better outcomes than those formerly randomized to placebo on primary double-blind study outcome measures.
Therefore, patients initially receiving placebo did not ''catch up'' with those receiving rivastigmine for the entire study. This underlines the importance of initiating treatment in AD as early as possible and remaining on consistent treatment for as long as possible.
Previous studies have demonstrated that nearly a third of patients do not stay on oral cholinesterase inhibitor treatment for more than 2 months, and that only half of patients complete 6 months of therapy without considerable gaps in medication. 20, 21 The rivastigmine patch offers the first once-daily transdermal treatment for AD patients, preferred over capsules by more than 70% of caregivers. 7 It empowers the caregiver in the administration of treatment and provides a visual reminder to treat. These factors, combined with a favorable long-term tolerability profile and sustained efficacy, could potentially improve compliance. Consistent with these observations, over 80% of patients entering the open-label extension phase completed the study at week 52.
The open-label design of the extension phase necessitates caution when interpreting the results, even though investigators, caregivers, and patients remained blinded to the initial allocation of double-blind phase treatment throughout the open-label extension. It is possible that patients who tolerated rivastigmine therapy or responded well to treatment would have been more likely to continue the trial and enter the open-label extension. However, the similarity between the baseline characteristics of the 1195 patients entering the initial double-blind study and the 870 entering the open-label extension suggests that patients continuing treatment were representative of the original population.
In conclusion, during the initial double-blind study, the 9.5 mg/24 h rivastigmine patch demonstrated comparable efficacy to the highest doses of oral capsules (12 mg/d), with a markedly improved tolerability profile. During the openlabel extension, the rivastigmine patch demonstrated a favorable long-term safety and tolerability profile and provided sustained treatment benefits in patients with AD for up to 1 year. It is recommended that patients on high rivastigmine capsule doses should be switched directly to the 9.5 mg/24 h patch, whereas de novo patients or those on low doses should undergo 4 weeks of 4.6 mg/24 h patch treatment before increasing to 9.5 mg/24 h. The rivastigmine patch provides easier access to optimal therapeutic doses and could potentially improve compliance allowing patients to stay on and benefit from treatment for longer. During the 28-week, open-label extension phase, the patch seemed to be well tolerated with a favorable safety profile.
